Schlaeppi J M, Eppenberger U, Martiny-Baron G, Küng W
Pharmaceuticals Research Laboratories, Ciba-Geigy, Basle, Switzerland.
Clin Chem. 1996 Nov;42(11):1777-84.
We developed a two-site chemiluminescence immunoassay for human vascular endothelial growth factor (VEGF). The assay recognized both VEGF121 and VEGF165 isoforms, but had no detectable cross-reactivity with platelet-derived growth factor or placenta growth factor. The range of detection was between 30 ng/L and 30 micrograms/L VEGF. Inter- and intraassay variations were 8.2-8.3% and 7.2-7.6%, respectively. VEGF concentrations were measured in the cytosolic extracts of 45 ovarian and 142 primary breast tumors. The amount of VEGF in the ovarian tumors (median = 0.46 ng/mg total protein, range 0-15.8 ng/mg) was significantly (P = 0.03) higher compared with the breast tumors (median = 0.24 ng/mg total protein, range 0-12.3 ng/mg). In 32 and 7 extracts of normal breast tissues adjacent and distant to the tumors, respectively, VEGF concentrations were significantly much lower (P < 0.0001). The detection of substantial amounts of VEGF in two invasive tumors (compared with normal tissues) suggests that the assay should be a useful tool for investigating the prognostic value of VEGF in breast and ovarian carcinomas and for selecting patients for future anti-VEGF therapy.
我们开发了一种用于检测人血管内皮生长因子（VEGF）的双位点化学发光免疫分析方法。该分析方法可识别VEGF121和VEGF165两种亚型，但与血小板衍生生长因子或胎盘生长因子无明显交叉反应。检测范围为30 ng/L至30 μg/L的VEGF。批间和批内变异分别为8.2 - 8.3%和7.2 - 7.6%。对45例卵巢肿瘤和142例原发性乳腺肿瘤的细胞溶质提取物中的VEGF浓度进行了测定。卵巢肿瘤中的VEGF含量（中位数 = 0.46 ng/mg总蛋白，范围0 - 15.8 ng/mg）显著高于乳腺肿瘤（中位数 = 0.24 ng/mg总蛋白，范围0 - 12.3 ng/mg）（P = 0.03）。在分别与肿瘤相邻和远离的32份和7份正常乳腺组织提取物中，VEGF浓度显著低得多（P < 0.0001）。在两种浸润性肿瘤中检测到大量VEGF（与正常组织相比）表明，该分析方法对于研究VEGF在乳腺癌和卵巢癌中的预后价值以及为未来抗VEGF治疗选择患者应是一种有用的工具。
